CoChat

Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study

Robert, Ph., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., Sichel, J. P., Rigal, F., Delaunay, J., Pagot, R., Aubin, B., Loo, H., Clerc, G., Brion, S., Houri, Z., Coffinet, P., Libert, C., Lanvin, F., Lepine, J. P., Catteau, J., Chabannes, J. P., Guibert, M., Hanus, M., May, J. P., Patris, M. F., Ropert, R., Amerongen, P. Van, Verdeau-Pailles, J., Boulogne, E., Dumont, P. · 1995 · International Clinical Psychopharmacology

The DOI matches its Crossref record.

Abstract

The aim of the present study was to determine whether, in patients with depression who had responded favourably to the selective serotonin reuptake inhibitor citalopram, there was a therapeutic benefit in continuation treatment. Three hundred and ninety-one depressive patients were included in an open short-term citalopram treatment period. Only patients who responded to treatment at 8 weeks (total score of 12 or less on the MADRS scale) were randomized to the 24 week double-blind phase. Seventy-four patients were treated with placebo and 152 with citalopram at the same constant dose to which the patient had responded in the first phase. Relapse was defined as a total score of 25 or more on the MADRS scale. Twenty-one patients (13.8%) continuing to receive citalopram relapsed compared with 18 patients (24.3%) receiving placebo. The log rank test for survival data used to test the quality of relapse hazards between the placebo group and the citalopram group showed that patients treated with citalopram had a significantly lower relapse rate (p = 0.04). The results of this study are in general agreement with those of other studies on antidepressants, and support the hypothesis that full dose continuation is more effective than placebo in preventing relapse of depression.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-199503001-00006

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 93

Metadata

Authors
Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., Sichel, J. P., Rigal, F., Delaunay, J., Pagot, R., Aubin, B., Loo, H., Clerc, G., Brion, S., Houri, Z., Coffinet, P., Libert, C., Lanvin, F., Lepine, J. P., Catteau, J., Chabannes, J. P., Guibert, M., Hanus, M., May, J. P., Patris, M. F., Ropert, R., Amerongen, P. V., Verdeau-Pailles, J., Boulogne, E., & Dumont, P.
Affiliations
  • Hôpital Pasteur (FR)
  • St Mary's Hospital (GB)
Venue
International Clinical Psychopharmacology
Published
1995-03
Volume
10
Pages
29-36
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2057287568
Cited by
85
References
0
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2 · 2019: 1 · 2017: 1 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 2
FWCI
2.09
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
citalopram, depression relapse prevention, continuation treatment, selective serotonin reuptake inhibitors, antidepressant maintenance, relapse rate, Montgomery-Asberg Depression Rating Scale, placebo comparison
MeSH terms
Adult, Aged, Depressive Disorder, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Time Factors, Citalopram

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. https://app.cochat.ai/papers/10.1097/00004850-199503001-00006
The paper
Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., Sichel, J. P., Rigal, F., Delaunay, J., Pagot, R., Aubin, B., Loo, H., Clerc, G., Brion, S., Houri, Z., . . . Dumont, P. (1995). Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199503001-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.